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Abstract
Background: Prader-Willi syndrome (MIM #176270; PWS) is caused by lack of the paternally-derived
copies, or their expression, of multiple genes in a 4 Mb region on chromosome 15q11.2. Known
mechanisms include large deletions, maternal uniparental disomy or mutations involving the imprinting
center. De novo balanced reciprocal translocations in 5 reported individuals had breakpoints clustering in
SNRPN intron 2 or exon 20/intron 20. To further dissect the PWS phenotype and define the minimal
critical region for PWS features, we have studied a 22 year old male with a milder PWS phenotype and a
de novo translocation t(4;15)(q27;q11.2).
Methods: We used metaphase FISH to narrow the breakpoint region and molecular analyses to map the
breakpoints on both chromosomes at the nucleotide level. The expression of genes on chromosome 15
on both sides of the breakpoint was determined by RT-PCR analyses.
Results: Pertinent clinical features include neonatal hypotonia with feeding difficulties, hypogonadism,
short stature, late-onset obesity, learning difficulties, abnormal social behavior and marked tolerance to
pain, as well as sticky saliva and narcolepsy. Relative macrocephaly and facial features are not typical for
PWS. The translocation breakpoints were identified within SNRPN intron 17 and intron 10 of a spliced
non-coding transcript in band 4q27. LINE and SINE sequences at the exchange points may have
contributed to the translocation event. By RT-PCR of lymphoblasts and fibroblasts, we find that upstream
SNURF/SNRPN exons and snoRNAs HBII-437 and HBII-13 are expressed, but the downstream snoRNAs
PWCR1/HBII-85 and HBII-438A/B snoRNAs are not.
Conclusion: As part of the PWCR1/HBII-85 snoRNA cluster is highly conserved between human and
mice, while no copy of HBII-438 has been found in mouse, we conclude that PWCR1/HBII-85 snoRNAs
is likely to play a major role in the PWS- phenotype.
Published: 06 May 2005
BMC Medical Genetics 2005, 6:18 doi:10.1186/1471-2350-6-18
Received: 20 January 2005
Accepted: 06 May 2005
This article is available from: http://www.biomedcentral.com/1471-2350/6/18
© 2005 Schüle et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medical Genetics 2005, 6:18 http://www.biomedcentral.com/1471-2350/6/18
Page 2 of 16
(page number not for citation purposes)
Background
Prader-Willi syndrome (PWS) is a complex neurodevelop-
mental disorder and a classic example for genomic
imprinting in humans. The incidence is about 1 in 10–
20,000, and the clinical manifestations include decreased
fetal activity, neonatal hypotonia, neonatal feeding diffi-
culties, hyperphagia with obesity, hypogonadism, short
stature, small hands and feet, characteristic facial features,
and mild to moderate mental retardation. Diagnostic cri-
teria have been proposed [1] and revised recently [2].
About 70% of individuals clinically diagnosed with PWS
have a ~4 Mb interstitial deletion at 15q11-13 of paternal
origin, with clustered breakpoints (BP) at either of two
proximal sites (BP1 or BP2) and one on the distal site
(BP3) (Fig. 1a). The majority of the remainder have mater-
nal uniparental disomy 15. In about 1 % of the cases, the
disease is due to aberrant imprinting and gene silencing.
Of these, 14% have small deletions in the imprinting
center (IC) region of the paternal allele that abolish the
expression of all imprinted paternally-expressed genes in
cis. In the remainder no demonstrable DNA sequence
changes have been observed [3-7]. In Angelman syn-
drome (AS, MIM#105830), which is usually caused by the
same mechanisms affecting the maternal chromosome
15, mutations in the maternal copy of a single gene,
UBE3A (MIM#601623), encoding a ubiquitin ligase, are
detected in about 5% of cases, whereas in PWS, no dis-
ease-causing mutations in a single imprinted gene have
yet been reported.
Three paternally expressed genes have been identified
between BP2 and SNRPN. These include MKRN3/
ZNF127 (MIM# 603856; Makorin 3 or Zinc finger protein
127) [8,9], MAGEL2/NDNL1 (MIM# 605283; MAGE-like
2 or Necdin-like 1) [10,11], and NDN (MIM# 602117;
Necdin) [12,13] (Figure 1a). The small nuclear ribonucle-
oprotein polypeptide N (MIM# 182279; SNRPN) gene
was the first gene with a known function to be mapped to
the PWS/AS deletion region, and is expressed from the
paternal chromosome only [14-17]. Multiple alternatively
spliced transcripts originate at the SNPRN promoter [18-
20]. The major SNRPN transcript is bi-cistronic encoding
two mRNA species. Exons 1–3 encode a protein product
of unknown function called SNURF (SNRPN upstream
reading frame). Exons 4–10 encode SmN, a homolog of
the SmB/B' protein that binds small nuclear RNAs
involved in pre-mRNA splicing. The largest transcripts
extend over a ~460 kb genomic region and include a large
3'UTR comprising up to 148 exons [19].
Multiple introns downstream of the SNURF-SNRPN cod-
ing region contain C/D box small nucleolar RNA
(snoRNA) genes. There are two multi-copy snoRNA clus-
ters (HBII-52 and PWCR1/HBII-85) [21,22], three single
copy snoRNA genes (HBII-436, HBII-13, and HBII-437),
and one snoRNA gene (HBII-438) present in two copies
that are 240 kb apart [19]. Since the snoRNAs are derived
from processed spliced-out introns, their expression is
controlled by the SNRPN promoter and is highest in
brain. The known function of other C/D box snoRNAs is
to guide 2'- O – ribose methylation of ribosomal RNA or
small nuclear RNA. This post-transcriptional modification
is conserved throughout evolution and is thought to con-
fer increased stability to the small RNA molecules [23].
The modification targets of the imprinted C/D box snoR-
NAs in the PWS/AS region are still unknown.
Spontaneous chromosome translocations can be
extremely valuable for assessing the contributions of indi-
vidual loci to the phenotype of microdeletion syndromes.
Five individuals with features of PWS have been reported
who have balanced reciprocal translocations with break-
points in the PWS/AS deletion region. All of them involve
the SNRPN locus. The breakpoints are located in intron 2
(proximal, n = 2), disrupting the SNURF/SNRPN coding
region, or in exon 20a/intron 20 (distal, n = 3) within the
3'-untranslated region of the long SNRPN transcript. One
individual with a proximal and two of three patients with
a distal breakpoint meet the diagnostic criteria for PWS
(score of 8 or more points) [20,24-28].
Here we report the clinical, cytogenetic and molecular
characterization of a 22 year old male with features of
PWS who has a different de novo balanced reciprocal trans-
location t(4;15)(q27;q11.2). We mapped the breakpoint
to SNRPN intron 17 (position on chr 15: 22803227,
UCSC Genome browser May 2004) and determined the
expression of snoRNAs on both sides of the breakpoint in
cultured fibroblasts and lymphoblasts.
Methods
Cytogenetic and FISH analysis
Metaphase spreads obtained from short-term blood lym-
phocyte cultures and Epstein-Barr virus (EBV)-trans-
formed lymphoblastoid cells (LCL) were processed for
high-resolution GTG- banding by standard methods. For
FISH studies, Bacterial Artificial Chromosomes (BACs)
were sourced from the RPCI-11 library and selected using
the UCSC Genome Browser, Assemblies: July 2003 and
May 2004). Fluorescence labelling, hybridization proce-
dures and imaging were performed as previously
described [29].
DNA methylation study
Genomic DNA was purified by phenol-chloroform extrac-
tion from LCLs from the study subject, a normal control,
and a PWS individual (Patient E in [6], Coriell Human
Mutant Cell Repository # GM12134). To investigate
methylation at exon 1 of SNRPN, 50 µg DNA were usedBMC Medical Genetics 2005, 6:18 http://www.biomedcentral.com/1471-2350/6/18
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for the bisulfite reaction and PCR with primers according
to standard protocols [30,31]. PCR products were sepa-
rated on a 3% agarose gel, stained with ethidium bro-
mide, and visualized under UV illumination.
Expression studies by RT-PCR and quantitative RT-PCR
Total RNA was extracted from LCL and primary fibroblast
cultures (FB) using RNA Stat 60. The RNA was treated with
DNaseI (Roche) and RT-PCR was performed using Super-
script II (Invitrogen). Primers were designed for exon-to-
exon amplification in an overlapping fashion – where
possible – for SNRPN, MKRN3, MAGEL2, NDN, snoR-
NAs, and two ESTs within Intron 20 of SNRPN (Table 1).
For a subset of exons in the SNPRN gene and the snoRNAs
HBII-13, HBII-437, and PWCR1/HBII-85, quantitative
Mapping the t(4;15) breakpoint and expression patterns of SNRPN exons and intronic genes Figure 1
Mapping the t(4;15) breakpoint and expression patterns of SNRPN exons and intronic genes . a . Schematic map 
of human chromosome region 15q11-q13. Black and gray circles represent imprinted genes, expressed from the paternal or 
maternal allele, respectively. White circles designate bi-allelically expressed genes. BP1, 2, and 3 indicate the locations of the 
deletion breakpoint hotspots [43]. b . FISH results placed BAC RP11-160D9 highlighted in green (nucleotide position 
22577151-22735621) proximal to the translocation breakpoint and RP11-876N20 highlighted in blue (position 22857334-
23036552) distal to the breakpoint. Intron 17, comprising nucleotides 22795282 to 22811656, thus is located ~ 63.4 kb down-
stream of RP11-160D9 and ~ 42 kb upstream of RP11-876N20. c . On representation of the SNRPN region (not drawn to 
scale) boxes represent exons and ESTs, lines represent snoRNA copies. Orange boxes and lines indicate exons, ESTs or snoR-
NAs tested for expression either by RT-PCR or quantitative RT-PCR. Black flash indicates the breakpoint in intron 17 of the 
SNRPN locus.BMC Medical Genetics 2005, 6:18 http://www.biomedcentral.com/1471-2350/6/18
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RT-PCR assays were performed with SYBR Green I™ dye in
an ABI 7700 cycler (Applied Biosystems) by using
standard protocols [32,33]. Primers were designed to
amplify products of 50 bp in length. GAPDH expression
was used as a reference. Each sample was run at least in
triplicate. The results were interpreted as described previ-
ously [28].
LCL RNA samples from a PWS individual with a microde-
letion of the imprinting center (GM12134), a normal
individual, an individual with an intrachromosomal trip-
lication of the PWS region on the paternally-derived chro-
mosome 15 (Patient 1 in [34], Coriell Human Mutant
Cell Repository # GM12135), and fibroblast RNA from
another t(4;15) PWS individual with the breakpoint in
intron 2 of SNRPN [27,28] served as controls.
Southern blot analysis
Southern blot analysis was performed according to stand-
ard methods with ExpressHyb™ solution (BD Bio-
sciences). Genomic DNA from a normal individual and
the t(4;15) carrier was cleaved in a double digestion with
restriction enzymes NheI and BsaWI to release a 6.4 kb
fragment, and with NheI and ApaI to release a 10 kb frag-
ment in the normal chromosome. The DNA probes were
synthesized by PCR from genomic DNA and cloned into
a pCRII T/A-vector (Invitrogen). The probes were
designed to hybridize within intron 16 (SB-1) and
upstream of the ApaI restriction site (SB-3) (Table 1).
Breakpoint cloning with a PCR-based method
Genomic DNA from a normal individual and the t(4;15)
carrier was cleaved in a double digestion with restriction
Table 1: Primers and conditions for PCR
RT-PCR 
Gene/Exon  fwd (5'-3')  rev (5'-3'); complement strand  size  T ann. 
ZNF127 GGG TTG CGG TTT TGC TAT TA TTT CTC GTG TGC TTC AAT GC 168 bp 59C
MAGEL2 CTG AAG CCT GGG ACT TTC TG GGA CCT TGG CCA CAA ACT TA 225 bp 59C
Necdin GAA GAA GCA CTC CAC CTT CG CCA TGA TTT GCA TCT TGG TG 164 bp 59C
SNRPN Ex 1–3 ATG GAG CGG GCA AGG GAT CGC GGT ACA ACT GAC ACT CTT GG 124 bp 53C
SNRPN Ex 14/16 CTG CAA ACA TAG GAG ATG ATA GTT CC CTT ATG AAA GCA CTG AGA TGA AGC C 459 bp 53C
SNRPN Ex 16/17 GAA AGT GAC CTA AAG AGT GTC ATT G CTT GCA GTT GGA CAG CCG ACT C 515 bp 53C
SNRPN Ex 17/18 AGA TAT CTT TAA AAT TGA GTC TTC TGT CCA TGA AGA TGC AGC ACT TTT GAA GAA 218 bp 53C
SNRPN Ex 19/20a CAT TGT GCT TAT TTA CTA TTT TTG TAG ACG CTG CAG GTG GTG ACC ATG TG 150 bp 53C
AK094315 TCT TCT CTA CCC TCA TTC CCA GC TCG CTA CAC CCC TTT GCT TAT G 222 bp 53C
AB061718 AGG AGG GGT TCA AAG ATG C CTG GTA AAC AAA CTG GTA AAG GTG 204 bp 50C
HBII-85/PWCR1 CGA TGA TGA GTC CCC CAT AAA AAC CAG TTC CGA TGA GAA CGA CG 79 bp 53C
HBII-13 GGA TTT GTG ATG AGC TGT GTT TAC GGA CTT CAG AGT AAT CAC GTT G 67 bp 54C
HBII-438A/B GGA TCG ATG ATG AGA ATA ATT ATT G GGA CCT CAG ATT GAC ATC TG 67 bp 53C
GABRB3 TCA GGC GGC ATT GGC GAT ACC ATA AAA ACT TGA CAG GCA GAG 352 bp 52C
GABRA5 AAT ATT GCC TTA ATG TTT CTA GCC TAT TCT ATT TCT TCG TGT 425 bp 48C
GABRG3 GCG TAT TCA CAT AGA CAT CTT G GAT TGG TCA CTA CTG GTC TGG 188 bp 52C
GAPDH TGG GCT ACA CTG AGC ACC AG GGG TGT CGC TGT TGA AGT CA 50 bp 53C
Quantitative RT-PCR 
Gene/Exon  fwd (5'-3')  rev (5'-3');complement strand  size  T ann. 
SNURF Ex2 ACG AAC TAC AGA ACA GCA CGT ACC CTG CGT TTG ACT TGG ACT TCC 50 bp 60C
SNURF Ex3 TTC TCA GCA GCA GCA AGT ACC T TGC CTC AGT TCA GCC TGG A 50 bp 60C
HBII-437 ATC ATT ATT TCT TGA ATT GG CCC TCA CGC TCC CTT TGC 50 bp 60C
SNRPN Ex 14/15 CTG CAA ACA TAG GAG ATG ATA GTT CC CAA AGA CGA TAA AAT GTT CCT TCT TG 50 bp 60C
SNRPN Ex 19/20a GGA ACC ACC ATT TGT CTA TGA TCC CTG CAG GTG GTG ACC ATG TG 50 bp 60C
HBII-438 ATA ATT GTC TGA GGA TGC T GAT TGA CAT CTG GAA TGA GTC 50 bp 60C
HBII-85/PWCR1 TCG ATG ATG AGT CCC CCA TAA CAT TTT GTT CAG CTT TTC CAA GG 50 bp 60C
PCR to generate Southern probes in intron 17 
Gene/Exon  fwd (5'-3')  rev (5'-3');complement strand  size  T ann. 
SB 1 ACC ATC AGT GAA TGA CCT GTT GC CCC AGC CTC TTT CCT ATG TCT TG 565 bp 53C
SB 3 TGG TAA ACT GAT GAG AGC ACA GCC GCC TGG GAG ACA GAA TGA GAA AC 416 bp 53CBMC Medical Genetics 2005, 6:18 http://www.biomedcentral.com/1471-2350/6/18
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enzymes EcoRV and ApaI, followed by adapter ligation
according to the manufacturer's instructions (BD Genome
Walker Universal Kit) [35]. A nested PCR reaction with
adapter primers and sequence-specific primers was per-
formed and the amplification products were cloned into
the pC2.1 T/A-vector (Invitrogen) after gel purification.
The clones were sequenced from both directions with uni-
versal primers from the vector (M13) and sequence spe-
cific primers.
Results
Clinical case report
The patient (Fig. 2) was born at 41 weeks of gestation with
a birth weight of 8 lb. Pregnancy was uneventful, but fetal
movements were somewhat reduced. In the newborn,
poor muscle tone, weak cry, excessive sleepiness, and
undescended testes were observed. During infancy, he had
poor suck and prolonged feeding times, but his weight
gain was satisfactory and he did not require tube feeding.
He was suspected to have absence seizures of about 20
seconds duration, along with proneness to giggling, some-
times with eye-rolling. These episodes resolved by four
years of age, and an EEG was normal.
He had a left esotropia that was surgically corrected. Dur-
ing childhood, sticky saliva, dry mouth, skin picking and
a marked tolerance to pain were noted and have persisted.
Excessive daytime somnolence continued beyond infancy
and treatment with amphetamine was started at 9 years of
age. A sleep study, at 13 years of age, was normal. In 2002,
a further sleep study and a multiple sleep latency tests
t(4;15) carrier at 15 years of age Figure 2
t(4;15) carrier at 15 years of age . Note absence of typical PWS facial features and presence of mild truncal obesity.BMC Medical Genetics 2005, 6:18 http://www.biomedcentral.com/1471-2350/6/18
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confirmed the diagnosis of narcolepsy. His daytime sleep-
iness has continued to respond to dexamphetamine.
Regarding his body weight, there was no rapid weight gain
between 1 and 6 years. Around 8 years of age, his interest
in food increased, and now he would keep eating if he had
unrestricted access to favorite sweet foods. He lives with
his parents who help to control his food intake. At 14.5
years, he had small hands and feet, at the 20th percentile
and 5th percentile, respectively, and showed mild truncal
obesity. His head circumference of 56.7 cm was at the 98th
percentile. Brain MRI scan was normal. At age 16 years, his
height was 155.7 cm and weight 65 kg. At the age of 22
years, his height is approximately 164 cm and his weight
has increased to 90 kg (BMI = 33.5).
At 13 years of age, he was found to have delayed puberty
and reduced linear growth velocity with his height falling
below the 3rd centile. Treatment with testosterone resulted
in improved height gain and genital development. At 15
years of age, he had a left orchidopexy and removal of a
dysplastic intra-abdominal right testis. He remains on 6
monthly testosterone implants because of reduced
hypothalamic function. He has never been on growth hor-
mone treatment.
Developmentally he had a mild delay in comparison to
his older siblings. He attended normal school but had
some difficulties due to rigid behaviours and poor peer
interactions. Psychological testing (WISC 111, Wide
Range Achievement test and BASC self report) revealed an
overall normal intellect. However, he had some involun-
tary fluctuation in attention and significant visual percep-
tual difficulties, e.g. deficits in visual organization, in
making sense of his visual world and transcribing visual
material. These perceptual problems have had a signifi-
cant effect on his learning and social life. At the age of 22,
he is attending a mainstream high school requiring extra
time and assistance in completing a diploma in informa-
tion technology. He is good at dismantling computers and
installing hardware, and prefers working on his computer
to socializing. Hyperphagia and skin picking are still a
challenge for him.
Cytogenetic analysis
High-resolution chromosome analysis showed an appar-
ently balanced reciprocal translocation between the long
arm of chromosome 4 and the proximal long arm of chro-
mosome 15. The breakpoints were assigned to chromo-
some bands 4q27 and 15q11: 46, XY, t(4;15)(q27;q11)
(Fig. 3a). Parental chromosomes were normal, indicating
that the patient's translocation was de novo.
a. High resolution G-banded ideograms and prometaphase chromosomes of the translocation derivatives and their normal  homologs Figure 3
a. High resolution G-banded ideograms and prometaphase chromosomes of the translocation derivatives and 
their normal homologs . An apparently balanced translocation t(4;15)(q27;q11) was identified with arrows indicating band 
location of breakpoints. b. DNA methylation analysis of CpG island of SNRPN promoter and exon 1. 1. The 174 bp 
PCR product is derived from the methylated maternal chromosome. 2. The 100 bp product is derived from the paternal chro-
mosome. PWS: PWS control, Normal: normal control, and t(4;15) carrier; H2O: no template control. The t(4;15) carrier 
shows the normal bi-parental methylation pattern.BMC Medical Genetics 2005, 6:18 http://www.biomedcentral.com/1471-2350/6/18
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DNA methylation analysis
To exclude alternative explanations for the phenotype,
such as an imprinting defect, DNA methylation analysis
was performed. Methylation-specific PCR of the SNURF-
SNRPN exon 1 region revealed a normal bi-parental
methylation pattern (Fig. 3b).
Mapping of the translocation breakpoint by FISH
We performed cytogenetic and molecular studies to char-
acterize the breakpoint at 15q11 in detail. Preliminary
FISH analysis showed that the breakpoint in 15q11 was
located between D15S11 and GABRB3, which flank the
SNRPN locus (data not shown). On this basis, a chromo-
some walking strategy was used across this region to nar-
row down the breakpoint region. We identified two BACs,
RP11-160D9 (current position 22577151-22735621 on
UCSC Genome Browser, May 2004 release) and RP11-
876N20 (current position 22857334-23036552), that
flanked the breakpoint and, thus, mapped it to a ~122 kb
interval (Fig. 1b).
Fine mapping of the breakpoint by SNRPN expression and 
Southern blot analysis
To further refine the breakpoint, we carried out quantita-
tive RT-PCR and RT-PCR experiments using RNA from an
LCL and skin fibroblasts (FB) for expression of SNRPN
transcripts. As shown in Figure 4 and Table 2, we found
expression of SNPRN exons 2, 3, and 14 to 17, but no
expression of exons 18 to 20, and concluded that the
breakpoint falls within intron 17. For mapping intron 17,
we designed a Southern blot using unique restriction sites.
DNA cleaved with NheI and BsaWI showed a 6.4 kb band
for the t(4;15) carrier and the normal control (Fig. 5b,
lanes 1 and 2), indicating that the breakpoint is located
downstream of the BsaWI site. Samples doubly digested
with NheI and ApaI (Fig. 5b, lanes 3–6), revealed addi-
tional bands for the translocation carrier. Besides the
expected 10 kb band derived from the normal chromo-
some 15, there was a ~11.5 kb band in lane 4, detected
with the SB-1 probe, and a ~7 kb band in lane 6, detected
with probe SB-3 (Fig. 5b). The novel ~11.5 kb band arose
from the der(15) chromosome, with an NheI site on the
chromosome 15 portion and an ApaI site on the chromo-
some 4 portion (Fig. 5c, upper panel). The novel band of
~7 kb arose from the der(4) chromosome, with an ApaI
site on the chromosome 15-part and an NheI site on the
chromosome 4-part. Taken together, these results delimit
the breakpoint region to ~3.6 kb between the BsaWI and
ApaI sites (Fig. 5a).
Breakpoint mapping at the nucleotide level
By DNA sequencing, we mapped the breakpoint to
SNRPN intron 17 (position chr 15: 22803227) and to
chromosome 4 at position chr. 4:123965881 (UCSC
Genome Browser, May 2004) (Fig. 6). On chromosome 4,
a long terminal repeat (LTR) retrotransposon, LTR1B,
spans the breakpoint. On chromosome 15, we found a
short interspersed element (SINE), AluY, and a long inter-
spersed element (LINE), L1M4, surrounding the break-
point (Fig. 6a). Thirty-nine bp upstream of the breakpoint
on chromosome 15 starts a common 26 bp core sequence
of Alu elements (Alu-DEIN) in an inverted orientation.
This sequence is known to be involved in gene rearrange-
ments [36]. While the sequence across the breakpoint is
contiguous on the der(15), an extra A is inserted on the
der(4) chromosome (Fig. 6b). Furthermore, the
breakpoint on chromosome 4 falls in a large intron
between exons 10 and 11 of a spliced transcript
(BC045668). By RT-PCR, we found that this transcript is
expressed in fibroblasts, but not in LCLs (data not
shown).
Expression of upstream genes MKRN3, MAGEL2, and 
NDN
Expression of the three imprinted genes MKRN3,
MAGEL2, and NDN upstream of SNRPN was tested by RT-
Table 2: SNRPN and snoRNA expression analysis with quantitative RT-PCR
Amplification product PWS Normal control t-PWS (4;15) PWS triplication t-PWS intron 2 t-PWS (4;15)
LCL LCL LCL LCL FB FB
SNURF Ex 2 0.0001 0.53 0.54 2 0.002 0.56
SNURF Ex 3 0.0002 1.1 1.43 6.4 0.0004 0.56
HBII-437 0.00003 0.86 1.13 4.9 0.00008 0.1
SNRPN 14/15 0.0013 4.7 4.91 17.23 - -
SNRPN 19/20a 0.005 1.34 0.003 4.7 0.007 0.007
HBII-438 0.03 1.5 0.02 6.2 0.07 0.07
PWCR1/HBII-85 0.03 3.7 0.02 16.8 0.04 0.06
Sample identification: PWS: PWS with an IC microdeletion (patient E in [5]); t(4;15) PWS: the PWS case reported here; PWS-triplication: 
intrachromosomal triplication of the PWS region [33]; t-PWS intron 2: previously reported PWS case with t(4;15)(q27;q11.2) and breakpoint in 
SNRPN intron 2 [26, 27]; LCL, lymphoblastoid cell line, FB, fibroblast strain. The numbers represent the ratio of target product to GAPDH control 
product.BMC Medical Genetics 2005, 6:18 http://www.biomedcentral.com/1471-2350/6/18
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PCR in t(4;15) fibroblasts and found to be indistinguish-
able from expression in normal control fibroblasts (data
not shown).
Expression of C/D box snoRNAs and intron-encoded ESTs
When testing for the intron-encoded C/D box snoRNAs,
we were able to document expression of HBII-13 and
HBII-437 and lack of expression for HBII-438A/B and
HBII-85/PWCR1 (Fig. 7). By use of a more sensitive
method, quantitative real-time RT-PCR, we obtained sim-
ilar results for the SNRPN  exons and snoRNAs tested
(Table 2). Two ESTs, AK094315 and AB061718 (= HBT8)
located in the 30 kb SNRPN intron 20 were not expressed
in the PWS control [6] and t(4;15) LCLs, but were
expressed in the normal control LCL (Fig. 7).
Discussion
Breakpoint mapping and mechanism of the translocation 
event
Dissecting the PWS deletion region and identifying indi-
vidual genes as responsible for parts of the phenotype rep-
resent a challenge because all reported smaller deletions
inactivate all imprinted genes on the paternally- derived
chromosome 15. Rare reciprocal translocations, therefore,
provide unique insights. We here report our studies of a
22 year old male with features of PWS who has a de novo
SNRPN expression analysis by RT-PCR of RNA from LCLs Figure 4
SNRPN expression analysis by RT-PCR of RNA from LCLs . On the left, the sizes of the PCR products are shown, and 
on the right, the location of the primers in SNRPN exons is listed. +RT: with reverse transcriptase; -RT: without reverse tran-
scriptase; H2O: no template control. All SNRPN +RT products tested were absent in the PWS control, and present in the nor-
mal control. The t(4;15) cells were positive for SNURF/ SNRPN exons 2–3, 15–16 and 16–17 and negative for exons 18 
through 20a. GAPDH primers were used as control for the integrity of the cDNA.BMC Medical Genetics 2005, 6:18 http://www.biomedcentral.com/1471-2350/6/18
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balanced reciprocal translocation t(4;15)(q27;q11.2).
This is the first such case where the translocation break-
points have been identified at the DNA sequence level.
The cytogenetic breakpoint designations in this individual
are identical to those in another male PWS-like case with
t(4;15)(q27;q11.2), previously reported by Kuslich and
colleagues [27] and restudied by Gallagher and colleagues
[28], which raised the intriguing possibility of a recurrent
translocation that may be facilitated by genomic repeats
or other distinct molecular features.
In the present case, however, we mapped the breakpoint
to  SNRPN  intron 17 (position on chr. 15: 22803227,
UCSC Genome Browser, May 2004) that differs from that
in the previous case (SNRPN intron 2). Furthermore, the
breakpoint in our case is novel as it does not fall into one
Southern blot analysis identifies breakpoint in SNRPN intron 17 Figure 5
Southern blot analysis identifies breakpoint in SNRPN intron 17 . a . Restriction map of the intron 17 region of the 
SNRPN gene on the normal chromosome 15. Black arrowheads indicate the boundaries of intron 17. The positions of the two 
hybridization probes (SB-1 and SB-3) are indicated by green lines. b . Lanes 1 and 2 contain double digests with NheI and BsaWI 
to release a fragment of 6.4 kb, lanes 3 and 4 contain double digests with NheI and ApaI to release a fragment of 10 kb. The 
membrane was probed with probe SB-1. The arrow indicates an additional band above the 10 kb fragment ~11.5 kb in length. 
The two bands are not well resolved on the rendition of this blot. This novel fragment is represented in c, upper panel. Lanes 
5 and 6 contain double digests with NheI and ApaI to release a 10 kb fragment. The membrane is probed with SB-3. The arrow 
indicates an additional band of ~ 7 kb. This novel fragment is represented schematically in c, lower panel. c . Schematic repre-
sentation of the junction fragments identified on the Southern blot in b. The upper panel represents the der(15) and the lower 
panel represents the der(4). Chromosome 15 material is indicated as a black line and material from chromosome 4 as a blue 
line. Location of restriction sites and of hybridization probes (green lines) are indicated.BMC Medical Genetics 2005, 6:18 http://www.biomedcentral.com/1471-2350/6/18
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of the two previously described "breakpoint clusters" in
intron 2 and exon 20a/intron 20 (Table 3 and Table 4).
On chromosome 4 (chr. 4 123965881), the LTR retro-
transposon LTR1B is spanning the breakpoint, and a short
interspersed element (SINE), AluY, and a LINE element,
L1M4, surround the breakpoint on chromosome 15 (Fig.
6). Interestingly, 39 bp upstream of the breakpoint on
chromosome 15 starts a common 26-bp core sequence of
Alu elements (Alu-DEIN) that has been shown to be
involved in gene rearrangements and has homology with
prokaryotic χ , an 8-bp sequence motif known to stimulate
recBC  mediated recombination in E. coli[37]. The core
sequence is identical to sequences in the left arm of the
consensus Alu element [38]. Sequence analyses of regions
directly adjacent to translocation breakpoints has shown
presence of the 26-bp Alu core sequence at or close
(within 20–50 bp downstream or upstream) to the sites of
recombination [36]. Therefore, this sequence might stim-
ulate homologous and non-homologous recombination
within the core or at nearby sites and could be the mech-
anism of recombination in the t(4;15) case reported here.
The translocation is de novo, as is true for all the previously
described cases with translocation breakpoints involving
the  SNPRN  gene. Given the PWS-like phenotype, the
translocation was assumed to be of paternal origin. This
Repeat sequences surrounding the breakpoint Figure 6
Repeat sequences surrounding the breakpoint . a . One hundred nucleotides on either side of the breakpoints on chro-
mosome 4 and 15 contain repetitive sequences (grey lines). The Alu-DEIN sequence is located 13–39 bp upstream of the 
breakpoint on chromosome 15. b . Sequence across the breakpoint on the der(4) chromosome reveals an additional A 
inserted at the breakpoint. Arrows indicate the direction centromere to telomere.BMC Medical Genetics 2005, 6:18 http://www.biomedcentral.com/1471-2350/6/18
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assumption was confirmed by the expression studies.
Paternal origin of the translocation was formally proven
in 2 of the 5 previously reported cases [26,27].
Karyotype – phenotype correlations
Two individuals with SNRPN intron 2 breakpoints were
described as having classical PWS, meeting the major
clinical criteria by age 3.5 years and additional minor clin-
ical criteria [25,27]. The individuals with a breakpoint in
SNRPN Exon 20/Intron 20 were described as having a
milder or atypical form of PWS (Table 3 and Table 4). The
weight gain started later than in classical PWS, at 7 and 5
years, respectively, for the patients described by Schulze et
al. 1996 and Wirth et al. 2001, and at 8 years in our case.
The characteristic facial features were absent in the case of
Wirth et al. 2001, and also in the present case. But this is
not a consistent feature in classical PWS, as in a
retrospective evaluation of 90 molecularly-proven PWS
cases, only 49% had the characteristic facial gestalt [39].
It is apparent from the review of the previously reported
cases and the individual reported here (Table 3 and Table
4) that some of these translocation cases tend to have a
milder, 'atypical' clinical picture, in comparison with clas-
sical PWS. There is not a complete absence of any of the
major phenotypic features (neonatal hypotonia and feed-
ing difficulty, hyperphagia from early childhood, obesity,
cognitive compromise, hypogenitalism), but the degree of
affection may be lower. None of the reported
translocation cases had any additional features that might
Expression analysis in LCLs of snoRNAs and two ESTs in intron 20 Figure 7
Expression analysis in LCLs of snoRNAs and two ESTs in intron 20 . RT-PCR analysis of the C/D box snoRNAs 
reveals expression of HBII-13, but not of HBII-438A/B, PWCR1/HBII-85 and the two ESTs in intron 20 in the t(4;15) transloca-
tion carrier. +RT: with reverse transcriptase; -RT: without reverse transcriptase; H2O: no template control.BMC Medical Genetics 2005, 6:18 http://www.biomedcentral.com/1471-2350/6/18
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possibly be attributed to disruption of a gene on the recip-
rocal chromosome, and in no prior case had an attempt
been made to identify a gene at this location.
Our sequence data mapped the breakpoint on chromo-
some 4 within intron 10 of a spliced polyadenylated tran-
script (BC045668). This unique cDNA clone represents a
Table 3: Clinical findings associated with paternally-derived de novo reciprocal translocations involving SNRPN
Breakpoint in SNRPN Intron 2 Breakpoint in SNRPN Exon 20/ Intron 20 Breakpoint in 
SNRPN Intron 17
Sun et al. 1996 Kuslich et al. 1999 Schulze et al. 1996 Conroy et al. 1997 Wirth et al. 2001 Present case
Karyotype 
designations
46, XY, t(15;19) 
(q12;q13.41)
46, XY, t(4;15) 
(q27;q11.2)
46, XY, t(9;15) 
(q21;q12–q13)
46, XY, t(2;15) 
(q37.2;q11.2)
46, X, t(X;15) 
(q28;q12)
46 XY, 
t(4;15)(q27;q11.2)
Age of 
examination
3.5 years 3 years 3 months 29 years 4.5 years 18 years 22 years
Major criteria (each scores one point) from [1] as revised in [2].
1. Neonatal 
central hypotonia
Floppy and 
lethargic in the 
first 6 months with 
poor suck (1pt.)
Hypotonicity, 
poor sucking 
reflex during 
infancy (1pt.)
Neonatal 
hypotonia (weak 
cry, poor suck) (1 
pt.)
Neonatal 
hypotonia, 
lethargy, poor 
suck (1 pt.)
- Reduced tone with 
poor head control, 
poor suck (1 pt.)
2. Infantile feeding 
problems/ failure 
to thrive
Failure to thrive 
(1pt.)
Feeding problems 
in infancy, failure 
to thrive (1 pt.)
Special feeding 
techniques, but no 
failure to thrive
- Feeding problems, 
but no failure to 
thrive (1pt.)
3. Rapid weight 
gain between 1–6 
years
Obesity starting at 
6 months, 
hyperphagia (1 pt.)
Eating behavior 
leading to 
increased weight 
gain at age 2 yr (1 
pt.)
Periodic excessive 
weight gain from 
age 7 yr
Onset of obesity 
at 1.5–2 yr with 
excessive appetite 
and food foraging 
(1 pt.)
Obesity began at 
4–5 yr with 
hyperphagia and 
food foraging (1 
pt.)
Late onset obesity 
(at approx. 8 yr)
4. Characteristic 
facial features
Narrow bifrontal 
diameter, almond-
shaped eyes, 
down-turned 
mouth (1pt.)
Narrow bifrontal 
diameter, almond-
shaped eyes, 
upslanted 
palpebral fissures 
(1 pt.)
Narrow bifrontal 
diameter, narrow 
face, small mouth, 
poor facial mimic 
(1pt.)
Narrow bifrontal 
diameter, squared 
nasal tip, 
downturned 
mouth (1 pt.)
--
5. Hypogonadism: 
genital hypoplasia, 
pubertal deficiency
Undescended 
testes (1 pt.)
Undescended 
small testes, 
hypogonadism (1 
pt.)
Hypoplastic 
genitalia, 
incomplete 
gonadal 
maturation with 
delayed pubertal 
signs after age 16 
yr (1 pt.)
Scrotum normal, 
penile length at 
10th %ile
Primary 
amenorrhea, 
hypoplastic uterus 
(1 pt.)
Undescended 
small testes, 
hypogonadism, 
delayed pubertal 
signs (1 pt.)
6. Mental 
retardation, 
developmental 
delay
Developmental 
delay (1 pt.)
Developmental 
delay (1 pt.)
Mental 
retardation, 
developmental 
delay/ learning 
problems (1 pt.)
Developmental 
delay, special 
school setting (1 
pt.)
Slight 
developmental 
delay, school for 
mentally retarded 
children (1 pt.)
Developmental 
delay, special 
school setting (1 
pt.)
Score 5 points 6 points 5 points 4 points 3 points 4 points
Blank cell = no information
- = absentBMC Medical Genetics 2005, 6:18 http://www.biomedcentral.com/1471-2350/6/18
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3764 bp mRNA from a human testis library that does not
appear to encode a protein. Its 5' end overlaps the inter-
leukin 21 (IL21) transcript by 511 bp in the opposite
direction (UCSC Genome Browser, May 2004). It appears
Table 4: Clinical findings associated with paternally-derived de novo reciprocal translocations involving SNRPN (continued)
Sun et al. 1996 Kuslich et al. 1999 Schulze et al. 1996 Conroy et al. 1997 Wirth et al. 2001 Present case
Minor criteria (1/2 point each)
1. Decreased fetal 
movement and 
infantile lethargy
Decreased fetal 
activity (0.5 pt.)
Decreased fetal 
movements 
(0.5pt.)
- - Slightly reduced 
fetal movements 
(0.5pt.)
2. Typical 
behaviour 
problems
Behavior problems 
(0.5pt.)
Temper tantrums, 
violent outbursts, 
obsessive-
compulsive (0.5 
pt.)
Aggressive 
outbursts, rigid 
personality, 
perseveration 
(0.5pt.)
Behavior problems 
with temper 
tantrums and 
severe 
aggressiveness (0.5 
pt.)
Temper tantrums, 
violent outbursts 
after food 
restrictions 
(0.5pt.)
Temper tantrums, 
abnormal social 
behavior (0.5pt.)
3. Sleep 
disturbance, sleep 
apnea
Sleep disturbance, 
sleep apnea 
(0.5pt.)
Sleep disturbance 
(0.5pt.)
Sleep disturbance, 
amphetamine 
treatment from 
age 9 ys. (0.5pt.)
4. Short stature 
for the family by 
age 15 years
Short stature at 
the age of 15 
(0.5pt.)
50–75th percentile 
(0.5pt.)
151 cm (3rd%tile) 
(0.5pt.)
Height 155.7 cm at 
16 years < 3rd 
%tile (0.5 pt.)
5. 
Hypopigmentation
- - Hypopigmentation 
(0.5 pt.)
--
6. Small hands and 
/or feet for height 
age
Hand length 25th 
percentile, finger 
length 10th%ile 
(0.5pt.)
- Normal hands, but 
small feet (< 
10th%tile) (0.5 pt.)
Short 3rd finger 
bilaterally
Hands 20th %ile, 
feet 5th %ile 
(0.5pt.)
7. Narrow hands 
with straight ulnar 
border
- -
8. Eye 
abnormalities: 
esotropia, myopia
- Esotropia (0.5 pt.) Alternating 
esotropia in 
infancy (0.5 pt.)
Left esotropia (0.5 
pt.)
Esotropia (0.5pt.)
9. Thick viscous 
saliva
Viscous saliva 
(0.5pt.)
Thick viscous 
saliva (0.5 pt.)
-
10. Speech 
articulation defect
Articulation 
difficulty (0.5 pt.)
Poor articulation 
(0.5pt.)
-
11. Skin picking Skin picking 
(0.5pt.)
Skin picking 
(0.5pt.)
Skin picking 
(0.5pt.)
Score (minor only) 1.5 points 3 points 3.5 points 2.5 points 1.5 points 3.5 points
Total Score 6.5 points 9 points 8.5 points 8.5 points 4.5 points 7.5 points
Blank cell = no information
- = absentBMC Medical Genetics 2005, 6:18 http://www.biomedcentral.com/1471-2350/6/18
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unlikely that heterozygous disruption of this gene con-
tributes to the phenotype in our patient.
Translocation has no effect on imprinting center 
methylation and upstream genes
To assess whether the translocation event had affected the
allele-specific methylation pattern at the imprinting
center (IC), and/or to exclude a coincident imprinting
defect, we carried out methylation studies of the SNRPN
exon 1 region that revealed a normal bi-parental methyl-
ation pattern. Similar results were reported for each of the
other five PWS individuals who had translocation break-
points within the SNRPN gene. These results predict that
expression of the genes located centromeric to the SNRPN
exon 1/ IC region, NDN, MAGEL2 and MKRN3, should
not be affected in these individuals. By studying t(4;15)
fibroblasts by RT-PCR, we indeed found expression of all
three genes. Previously, only MKRN3 was reported to be
expressed in the three PWS translocation cases in which it
was studied [20,25,27].
In t(4;15) lymphoblasts, the SNRPN transcript was detect-
able by RT-PCR and quantitative RT-PCR and found to
extend all the way to exon 17. The major transcript that
encodes the SNURF/SNRPN proteins terminates in exon
10 [20] and, therefore, should be unaffected by this
t(4;15) translocation. With the caveat that studies on
peripheral tissues, fibroblasts and lymphoblasts, may not
accurately reflect gene expression in the brain, our results
indicate that SNURF/SNRPN and the centromeric genes
MKRN3, NDN and MAGEL2 are unlikely to play a prime
role in the causation of PWS-associated features, although
it remains an open question whether their loss or non-
functioning might contribute to the more marked pheno-
typic expression that is seen in typical PWS.
Genes downstream of the breakpoint are not expressed
With respect to expression of downstream transcripts, the
reported results on LCLs with breakpoints in exon 20/
intron 20 were consistent, whereas for the two patients
with breakpoints in intron 2, the reported results were
conflicting for expression of downstream transcripts IPW
and PAR-1. In a re-evaluation of the t(4;15) case reported
by Kuslich and colleagues [26], no expression of these
transcripts and of the PWCR1/HBII-85 snoRNA cluster
was detected by real-time quantitative RT-PCR [28].
Therefore, we focused our analysis on the snoRNAs and
two ESTs in intron 20. As for the intron-encoded C/D box
snoRNAs, HBII-13 and HBII-437 were expressed, and
HBII-438A/B and HBII-85/PWCR1 were not. HBII-52
snoRNAs were not studied, as they are not expressed in the
available tissues and have previously been excluded from
contributing to the PWS phenotype [40,41]. The two ESTs
in the large intron 20 that are highly expressed in brain
tissues [42] were found to be expressed in a normal con-
trol LCL, but not in the t(4;15) LCL. This result suggests
that these ESTs do not have their own promoter but are
dependent on transcription from the SNRPN promoter
that is located on the other translocation derivative in
these cells. Therefore, these ESTs most likely represent sta-
ble derivatives of large alternatively spliced non-coding
SNRPN transcripts.
Conclusion
(1) Expression of the ESTs and/or C/D box snoRNAs that
are located downstream of the translocation breakpoint is
not necessary for establishing and maintaining the pater-
nal-specific pattern of gene expression pattern that is
controlled by the imprinting center upstream of the trans-
location breakpoint.
(2) The C/D box snoRNAs HBII-438A and PWCR1/HBII-
85 are the only stable transcripts in this region that are dis-
rupted in this t(4;15) PWS individual. As PWCR1/HBII-85
sequences are highly conserved between human and
mice, while no copy of HBII-438A has been found in
mouse, we conclude that the basis of PWS pathogenesis
resides, in whole or in part, in the absence of PWCR1/
HBII-85 snoRNA. SNURF/SNRPN  and the centromeric
genes MKRN3, NDN and MAGEL2 are unlikely to play a
major role in the causation of PWS-associated features.
While the function of known C/D box snoRNAs is to
guide 2'- O -ribose methylation of mainly ribosomal RNA,
these novel imprinted snoRNAs have no known target.
They might be involved in a posttranscriptional
regulation process of a gene or genes that – if non-func-
tional – gives rise to the PWS phenotype.
Competing interests
The author(s) declare that they have no competing
interests.
Authors' contributions
BS carried out the molecular genetic studies (RT-PCR,
methylation assay, Southern blot analysis, and breakpoint
analysis) and drafted the manuscript. MA carried out
quantitative RT-PCR assays. EN performed the FISH anal-
ysis with BAC clones. DIF carried out the initial cytoge-
netic analysis. MR revised the clinical data and re-
examined the patient.
HRS supervised the cell culturing, cytogenetic and FISH
studies. RJMG diagnosed the patient, collected the clinical
data and obtained skin and blood samples. UF conceived
the study design, and coordinated its progress, supervised
the work of BS and MA and prepared the final manuscript.
Acknowledgements
We are indebted to the family participating in this study and to Prof. 
George A. Werther who referred the patient to us, and in his letter wrote BMC Medical Genetics 2005, 6:18 http://www.biomedcentral.com/1471-2350/6/18
Page 15 of 16
(page number not for citation purposes)
"I wonder whether this translocation may involve the Prader-Willi gene". 
The work in the laboratory of UF was supported by grants from the NIH 
(HD41623) and the Deutsche Forschungsgemeinschaft (BS – SCHU 1567/
1-1).
References
1. Holm VA, Cassidy SB, Butler MG, Hanchett JM, Greenswag LR, Whit-
man BY, Greenberg F: Prader-Willi syndrome: consensus diag-
nostic criteria. Pediatrics 1993, 91:398-402.
2. Cassidy SB: Prader-Willi syndrome. 2001:301-322.
3. Ledbetter DH, Riccardi VM, Airhart SD, Strobel RJ, Keenan BS, Craw-
ford JD: Deletions of chromosome 15 as a cause of the
Prader-Willi syndrome. N Engl J Med 1981, 304:325-329.
4. Buiting K, Gross S, Lich C, Gillessen-Kaesbach G, el-Maarri O,
Horsthemke B: Epimutations in Prader-Willi and Angelman
syndromes: a molecular study of 136 patients with an
imprinting defect. Am J Hum Genet 2003, 72:571-577.
5. Mascari MJ, Gottlieb W, Rogan PK, Butler MG, Waller DA, Armour
JA, Jeffreys AJ, Ladda RL, Nicholls RD: The frequency of uniparen-
tal disomy in Prader-Willi syndrome. Implications for molec-
ular diagnosis. N Engl J Med 1992, 326:1599-1607.
6. Sutcliffe JS, Nakao M, Christian S, Orstavik KH, Tommerup N, Led-
better DH, Beaudet AL: Deletions of a differentially methylated
CpG island at the SNRPN gene define a putative imprinting
control region [see comments]. Nat Genet 1994, 8:52-58.
7. Buiting K, Saitoh S, Gross S, Dittrich B, Schwartz S, Nicholls RD,
Horsthemke B: Inherited microdeletions in the Angelman and
Prader-Willi syndromes define an imprinting centre on
human chromosome 15 [published erratum appears in Nat
Genet 1995  10:249]. Nat Genet 1995, 9:395-400.
8. Jong MT, Carey AH, Caldwell KA, Lau MH, Handel MA, Driscoll DJ,
Stewart CL, Rinchik EM, Nicholls RD: Imprinting of a RING zinc-
finger encoding gene in the mouse chromosome region
homologous to the Prader-Willi syndrome genetic region.
Hum Mol Genet 1999, 8:795-803.
9. Jong MT, Gray TA, Ji Y, Glenn CC, Saitoh S, Driscoll DJ, Nicholls RD:
A novel imprinted gene, encoding a RING zinc-finger pro-
tein, and overlapping antisense transcript in the Prader-Willi
syndrome critical region. Hum Mol Genet 1999, 8:783-793.
10. Boccaccio I, Glatt-Deeley H, Watrin F, Roeckel N, Lalande M, Musc-
atelli F: The human MAGEL2 gene and its mouse homologue
are paternally expressed and mapped to the Prader-Willi
region. Hum Mol Genet 1999, 8:2497-2505.
11. Lee S, Kozlov S, Hernandez L, Chamberlain SJ, Brannan CI, Stewart
CL, Wevrick R: Expression and imprinting of MAGEL2 suggest
a role in prader-willi syndrome and the homologous murine
imprinting phenotype. Hum Mol Genet 2000, 9:1813-1819.
12. Jay P, Rougeulle C, Massacrier A, Moncla A, Mattei MG, Malzac P,
Roeckel N, Taviaux S, Lefranc JL, Cau P, Berta P, Lalande M, Muscatelli
F: The human necdin gene, NDN, is maternally imprinted
and located in the Prader-Willi syndrome chromosomal
region. Nat Genet 1997, 17:357-361.
13. MacDonald HR, Wevrick R: The necdin gene is deleted in
Prader-Willi syndrome and is imprinted in human and
mouse. Hum Mol Genet 1997, 6:1873-1878.
14. Özçelik T, Leff SE, Robinson WP, Donlon T, Lalande M, Sanjines E,
Schinzel A, Francke U: Small nuclear ribonucleoprotein
polypeptide N (SNRPN), an expressed gene in the Prader-
Willi syndrome critical region. Nature Genet 1992, 2:265-269.
15. Nakao M, Sutcliffe JS, Durtschi B, Mutirangura A, Ledbetter DH,
Beaudet AL: Imprinting analysis of three genes in the Prader-
Willi/Angelman region: SNRPN, E6-associated protein, and
PAR-2 (D15S225E). Hum Mol Genet 1994, 3:309-315.
16. Reed ML, Leff SE: Maternal imprinting of human SNRPN, a
gene deleted in Prader-Willi syndrome.  Nat Genet 1994,
6:163-167.
17. Glenn CC, Saitoh S, Jong MT, Filbrandt MM, Surti U, Driscoll DJ,
Nicholls RD: Gene structure, DNA methylation, and
imprinted expression of the human SNRPN gene. Am J Hum
Genet 1996, 58:335-346.
18. Gray TA, Saitoh S, Nicholls RD: An imprinted, mammalian bicis-
tronic transcript encodes two independent proteins. Proc Natl
Acad Sci U S A 1999, 96:5616-5621.
19. Runte M, Huttenhofer A, Gross S, Kiefmann M, Horsthemke B, Buit-
ing K: The IC-SNURF-SNRPN transcript serves as a host for
multiple small nucleolar RNA species and as an antisense
RNA for UBE3A. Hum Mol Genet 2001, 10:2687-2700.
20. Wirth J, Back E, Huttenhofer A, Nothwang HG, Lich C, Gross S, Men-
zel C, Schinzel A, Kioschis P, Tommerup N, Ropers HH, Horsthemke
B, Buiting K: A translocation breakpoint cluster disrupts the
newly defined 3' end of the SNURF-SNRPN transcription
unit on chromosome 15. Hum Mol Genet 2001, 10:201-210.
21. de Los Santos T, Schweizer J, Rees CA, Francke U: Small evolution-
arily conserved RNA, resembling C/D box small nucleolar
RNA, is transcribed from PWCR1, a novel imprinted gene in
the Prader-Willi deletion region, which is highly expressed in
brain. Am J Hum Genet 2000, 67:1067-1082.
22. Cavaille J, Buiting K, Kiefmann M, Lalande M, Brannan CI, Horsthemke
B, Bachellerie JP, Brosius J, Huttenhofer A: Identification of brain-
specific and imprinted small nucleolar RNA genes exhibiting
an unusual genomic organization. Proc Natl Acad Sci U S A 2000,
97:14311-14316.
23. Kiss T: Small Nucleolar RNAs:  An Abundant Group of Non-
coding RNAs with Diverse Cellular Functions.  Cell 2002,
109:145-148.
24. Schulze A, Hansen C, Skakkebaek NE, Brondum-Nielsen K, Ledbeter
DH, Tommerup N: Exclusion of SNRPN as a major determi-
nant of Prader-Willi syndrome by a translocation
breakpoint. Nat Genet 1996, 12:452-454.
25. Sun Y, Nicholls RD, Butler MG, Saitoh S, Hainline BE, Palmer CG:
Breakage in the SNRPN locus in a balanced 46,XY,t(15;19)
Prader-Willi syndrome patient. Hum Mol Genet 1996, 5:517-524.
26. Conroy JM, Grebe TA, Becker LA, Tsuchiya K, Nicholls RD, Buiting
K, Horsthemke B, Cassidy SB, Schwartz S: Balanced translocation
46,XY,t(2;15)(q37.2;q11.2) associated with atypical Prader-
Willi syndrome. Am J Hum Genet 1997, 61:388-394.
27. Kuslich CD, Kobori JA, Mohapatra G, Gregorio-King C, Donlon TA:
Prader-Willi syndrome is caused by disruption of the
SNRPN gene. Am J Hum Genet 1999, 64:70-76.
28. Gallagher RC, Pils B, Albalwi M, Francke U: Evidence for the role
of PWCR1/HBII-85 C/D box small nucleolar RNAs in Prader-
Willi syndrome. Am J Hum Genet 2002, 71:669-678.
29. Li L, Moore P, Ngo C, Petrovic V, White SM, Northrop E, Ioannou
PA, McKinlay Gardner RJ, Slater HR: Identification of a haplosuf-
ficient 3.6-Mb region in human chromosome 11q14.3-->q21.
Cytogenet Genome Res 2002, 97:158-162.
30. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW,
Molloy PL, Paul CL: A genomic sequencing protocol that yields
a positive display of 5-methylcytosine residues in individual
DNA strands. Proc Natl Acad Sci U S A 1992, 89:1827-1831.
31. Kubota T, Das S, Christian SL, Baylin SB, Herman JG, Ledbetter DH:
Methylation-specific PCR simplifies imprinting analysis. Nat
Genet 1997, 16:16-17.
32. Bustin SA: Absolute quantification of mRNA using real-time
reverse transcription polymerase chain reaction assays. J Mol
Endocrinol 2000, 25:169-193.
33. Ginzinger DG: Gene quantification using real-time quantita-
tive PCR: an emerging technology hits the mainstream. Exp
Hematol 2002, 30:503-512.
34. Ungaro P, Christian SL, Fantes JA, Mutirangura A, Black S, Reynolds J,
Malcolm S, Dobyns WB, Ledbetter DH: Molecular characterisa-
tion of four cases of intrachromosomal triplication of chro-
mosome 15q11-q14. J Med Genet 2001, 38:26-34.
35. Siebert PD, Chenchik A, Kellogg DE, Lukyanov KA, Lukyanov SA: An
improved PCR method for walking in uncloned genomic
DNA. Nucleic Acids Res 1995, 23:1087-1088.
36. Rüdiger NS, Gregersen N, Kielland-Brandt MC: One short well
conserved region of Alu-sequences is involved in human
gene rearrangements and has homology with prokaryotic
chi. Nucleic Acids Res 1995, 23:256-260.
37. Dower NA, Stahl FW: Chi activity during transduction-associ-
ated recombination. Proc Natl Acad Sci U S A 1981, 78:7033-7037.
38. Deininger PL, Jolly DJ, Rubin CM, Friedmann T, Schmid CW: Base
sequence studies of 300 nucleotide renatured repeated
human DNA clones. J Mol Biol 1981, 151:17-33.
39. Gunay-Aygun M, Schwartz S, Heeger S, O'Riordan MA, Cassidy SB:
The changing purpose of Prader-Willi syndrome clinical
diagnostic criteria and proposed revised criteria.  Pediatrics
2001, 108:E92.
40. Hamabe J, Kuroki Y, Imaizumi K ,  S u g i m o t o  T ,  F u k u s h i m a  Y ,
Yamaguchi A, Izumikawa Y, Niikawa N: DNA deletion and itsPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medical Genetics 2005, 6:18 http://www.biomedcentral.com/1471-2350/6/18
Page 16 of 16
(page number not for citation purposes)
parental origin in Angelman syndrome patients. Am J Med
Genet 1991, 41:64-68.
41. Runte M, Varon R, Horn D, Horsthemke B, Buiting K: Exclusion of
the C/D box snoRNA gene cluster HBII-52 from a major role
in Prader-Willi syndrome. Hum Genet 2005, 116:228-230.
42. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Waka-
matsu A: Complete sequencing and characterization of
21,243 full-length human cDNAs.  Nature Genetics 2004,
36:40-45.
43. Chai JH, Locke DP, Greally JM, Knoll JH, Ohta T, Dunai J, Yavor A,
Eichler EE, Nicholls RD: Identification of four highly conserved
genes between breakpoint hotspots BP1 and BP2 of the
Prader-Willi/Angelman syndromes deletion region that
have undergone evolutionary transposition mediated by
flanking duplicons. Am J Hum Genet 2003, 73:898-925.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2350/6/18/prepub